What is Longboard Pharmaceuticals Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Longboard Pharmaceuticals's annualizedGross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil.
Longboard Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2024 was $189.18 Mil. Therefore, Longboard Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.
Longboard Pharmaceuticals Gross-Profit-to-Asset % Historical Data
The historical data trend for Longboard Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Longboard Pharmaceuticals's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Longboard Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longboard Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Longboard Pharmaceuticals's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Longboard Pharmaceuticals Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LBPH has been successfully added to your 